Physician profile
Richard H Wang
NPI 1235208455
$4,488.43
in general payments reported to CMS, 2019-2025
16 companies · $902 in 2025
The $902 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $200 · 2021: $362 · 2022: $676 · 2023: $634 · 2024: $820 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.74 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,677.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $495.47 | 2023-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $357.27 | 2020-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $230.17 | 2019-2024 | Jardiance, Mounjaro |
| Amarin Pharma, INC. | $182.88 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $176.81 | 2019-2023 | Belsomra, Steglatro |
| Abbvie INC. | $144.54 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $41.87 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.69 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.82 | 2024 | |
| Janssen Pharmaceuticals, INC | $29.12 | 2019 | |
| Amgen INC. | $20.77 | 2019 | |
| Phadia US INC. | $19.46 | 2019 | |
| Genentech USA, INC. | $17.81 | 2020 | |
| Horizon Therapeutics Plc | $15.00 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.